Company profile
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Roflumilast | approved | — | 35 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (25)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03764475 | phase2 | completed | 2018-12-18 | 2020-10-08 | Arcutis Biotherapeutics, Inc. | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis |
| NCT04445987 | phase2 | completed | 2020-06-12 | 2022-11-19 | Arcutis Biotherapeutics, Inc. | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis |
| NCT07340216 | phase1 | completed | 2025-12-15 | 2026-04-30 | Arcutis Biotherapeutics, Inc. | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis |
| NCT04279119 | phase1 | completed | 2020-03-10 | 2021-03-25 | Arcutis Biotherapeutics, Inc. | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis |
| NCT04655313 | phase2 | completed | 2020-11-30 | 2022-01-12 | Arcutis Biotherapeutics, Inc. | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 215985 | NDA | ARCUTIS BIOTHERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 217242 | NDA | ARCUTIS BIOTHERAPEUTICS INC | ||||
Loading… | ||||||